Tris Pharma logo

Expand your market reach with Tris’ innovative technologies

Open up new market segments by offering sustained release products in alternative dosage forms for patients having difficulty swallowing pills. Our innovative OralXR+ technology offers sustained release in a variety of dosage forms such as liquid, chewable tablets, strips and ODT.

Protect your products from intentional and unintentional abuse

Nobuse™ is an abuse resistant proprietary technology applicable to all controlled substances and opiates for all oral dosage forms in immediate and sustained release versions.

nobuse

News & Events

Submission of TuzistraTM XR (CCP-01) NDA to FDA Read More

Tris Pharma Expands R&D Team with addition of Chief Medical Officer and Vice President of Regulatory Affairs Read More

Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept Read More

Tris Pharma Announces Management Changes Read More

Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 Read More

Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension Read More

Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution Read More

Tris Pharma Hires President for Generic Pharmaceuticals Business Read More

Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey Read More

FDA Approves Tris Pharma’s New Drug Application for KarbinalTM ER (carbinoxamine maleate) Extended-release Oral Suspension Read More

First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris Read More

Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States Read More

Tris Pharma Appoints New Vice President of Business Development (November 2012) Read More

Pfizer To Acquire NextWave Pharmaceuticals, Inc. (October 2012) Read More

NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR™ for Once-Daily Treatment of ADHD (October 2012) Read More

Perrigo and Tris Pharma launch store brand version of Delsym® (August 2012) Read More

Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals (July 2012) Read More

Tris Pharma to Hold Job Fairs - Saturday June 16 and Saturday June 23 (June 2012) Read More

Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension (May 2012) Read More

Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension (May 2012) Read More

Tris Pharma Announces Management Additions, Promotion (April 2012) Read More

Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market (February 2012) Read More

Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive (January 2012) Read More

Tris Pharma Announces US Patent Grant Covering Platform Technology (January 2012) Read More

Tris Pharma Expands Leadership Team, Adds Senior Managers in Quality and Finance (August 2011) Read More

Extend your power to innovate

As a pioneer in the development of sustained release oral dosage forms, we dream big, never give up and relish in solving the unsolvable... Read More